



Aim: To characterise clinically the patients with C4d
in peritubular capillaries deposits (C4dPTCD) and/or
circulating anti-HLA class I/II alloantibodies. To deter-
mine the correlation between positive C4dPTCD and
circulating anti-HLA class I/II alloantibodies during
episodes of graft dysfunction
Subjects and Methods: C4d staining was performed
in biopsies with available frozen tissue obtained
between January 2004 and December 2006. The study
was prospective from March 2005, when a serum sam-
ple was obtained at the time of biopsy to detect cir-
culating anti-HLA class I/II alloantibodies.
Results: We studied 109 biopsies in 86 cadaver renal
transplant patients. Sixteen of these (14.7%) presented
diffuse positive C4dPTCD. There was a 13.5% rate 
of +C4dPTCD incidence within the first six months of
transplantation and 16% after six months (p>0.05). Half
of the +C4dPTCD in the first six months was associated
with acute humoral rejection. After six months, the 
majority of +C4dPTCD (n=7/8) was present in biopsies
with evidence of interstitial fibrosis/tubular atrophy
and/or transplant glomerulopathy. The C4dPTCD was
more frequent in patients with positive anti-HCV anti-
bodies (p<0.0001), a previous renal transplant (p=
0.007), and with a panel reactivity antibody (PRA) ≥ 50%
(p=0.0098). The anti-HCV+ patients had longer time 
on dialysis (p=0.0019) and higher PRA (p=0.005). Cir-
culating anti-HLA I/II alloantibodies were screened in 46
serum samples. They were positive in 10.9% of sam-
ples, all obtained after six months post transplant. Cir-
culating alloantibodies were absent in 92.5% of the C4d
negative biopsies.
Conclusion: We found an association between the
presence of C4dPTCD and 2nd transplant recipients,
higher PRA and the presence of anti-HCV antibodies.
The presence of HCV antibodies is not a risk factor
for C4dPTCD per se, but appears to reflect longer
time on dialysis and presensitisation. In renal dys-
function a negative alloantibody screening is asso-
ciated with a reduced risk of C4dPTCD (<10%).
Key-Words:
Alloantibodies; C4d; hepatitis C; humoral rejection;
kidney transplant. 
 INTRODUCTION
Allograft rejection has been considered predomi-
nantly a T cell centred process over the last five
decades. However, in the last few years the impor-
tance of antibody mediated mechanism has been
rediscovered, partly due to the improved ability to
detect antibody activity with C4d staining, and the
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advent of more sensitive methods of detecting cir-
culating antibodies. 
At present, four types of antibody-mediated graft
injury have been defined: hyperacute rejection, acute
humoral rejection, chronic humoral rejection and
accommodation1. In general, antibody-mediated rejec-
tion has a worse prognosis than and requires a dif-
ferent form of therapy from the usual T cell-mediated
acute rejection.
Within the past decade, reports on the usefulness
of PTC C4d staining have emerged. C4d is a frag-
ment of C4b, an activation product of the classic com-
plement pathway. C4b and C4d form a covalent bond
with nearby proteins after activation by antibody and
C1 complex. C4b/C4d remains bound in the tissue for
several days after Ig and C1 complex have been
released. No functional role for C4d per se has been
reported. The use of immunofluorescence with mono-
clonal antibody in frozen tissue section is the bet-
ter method for its detection2. 
The pioneering studies of Feucht et al.3 described
for the first time the value of capillary deposition of
C4d in graft prognosis. Magil et al.4 were also among
those to report that C4d is an important predictor
of graft survival, having predictive value independ-
ent of several other morphological and clinical 
factors. They found an association between being
positive for C4d, female gender, panel reactivity anti-
bodies (>30%), and resistance to standard anti-
-rejection therapy. 
Colvin et al.5 were the first to demonstrate a clear
correlation between PTC C4d staining with concur-
rent circulating anti-donor-specific antibody (DSA) and
certain pathological features defining the main char-
acteristics of acute humoral rejection: neutrophils in
peritubular and glomerular capillaries and vascular
and arterial fibrinoid necrosis. 
C4d deposition is strongly associated with circulat-
ing antibody to donor HLA class I or class II antigens
and is currently the best single marker of complement-
fixing circulating antibodies to the endothelium1.
We now know that alloantibodies preferentially
react with the endothelium of peritubular and glomeru-
lar capillaries, in contrast to T cells which character-
istically infiltrate tubules and arterial endothelium. 
Overall, the newer and more sensitive techniques
for serum antibody screening allow for a clearer
understanding of the relationship between antibod-
ies and acute or chronic allograft rejection6. 
 SUBJECTS AND METHODS 
The study was retrospective between January 2004
and March 2005. From then until December 2006 the
study was prospective, with routine assessment of
C4d presence in all biopsies performed for allograft
dysfunction, and simultaneous screening for circulat-
ing anti-HLA I/II antibodies. 
 Patients and biopsies
744 kidney transplantations had been performed
in Hospital Curry Cabral, Lisbon by December 2006;
206 biopsies were performed for allograft dysfunc-
tion or delayed graft function between January 2004
and December 2006. Allograft dysfunction was
defined as unexplained and persistent (more than 3
days) increase of serum creatinine level above 30%
baseline. Delayed graft function was defined as fail-
ure to achieve a creatinine level under 2 mg/dl at
ten days post transplant, or dialysis requirement with-
in the first ten days post transplant.
We evaluated all the biopsies with available frozen
tissue in this period (n=109). 
The following clinical parameters were registered
at biopsy time: 1) patient age; 2) patient gender; 3)
race; 4) underlying renal disease; 5) duration of end
stage renal failure; 6) duration of post transplanta-
tion follow up; 7) previous kidney transplantation; 8)
HCV status; 9) panel reactivity antibodies; 10) serum
creatinine levels; 11) immunosuppressive treatment.
 Renal allograft pathology and C4d staining
A needle biopsy core was obtained from each renal
allograft for morphological studies. The biopsy core
was divided in two parts, one for formalin fixation and
one for quick freezing. Haematoxylin/eosin, periodic
acid Schiff, Masson’s trichrome and sliver stains were
routinely used for formalin-fixed tissue. Fresh-frozen
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tissue was analysed by immunofluorescence (IF)
microscopy using antibodies against immunoglobulin
(Ig) IgG, IgA, IgM, complement component (C) C3c, C4c,
and C1q.
C4d staining was performed on frozen slides,
using an indirect 2-step IF technique with a pri-
mary affinity-purified monoclonal antibody (mouse
anti-human; dilution 1:30; 30-min. incubation at
room temperature; Quidel®, CA 92121, USA) and a
fluorescein isothiocyanate-labeled affinity-purified
secondary horse anti-mouse IgG antibody (1:50; 30-
min. incubation at room temperature; Vector®, FI
2080, USA).
Diffuse positive C4d staining was defined as bright
linear staining along capillary basement membranes,
involving over half of sampled capillaries, according
to the international consensus criteria based on dis-
cussions at the Banff Conference on Allograft Pathol-
ogy in 2005-2007.
 Circulating anti-HLA alloantibodies and donor
specific antibodies
A serum sample has been obtained at the time
of biopsy to detect the presence of circulating anti-
HLA class I/II alloantibodies by flow cytometric assay
(FlowPRA® screening test) since March 2005. In sus-
pected cases of acute humoral rejection biopsies, the
circulating donor specific and anti-donor HLA anti-
bodies are determined by flow cytometry.
 Statistical analysis
Analysis of data was carried out using the Med-
Calc Software 9.0.1.1. Descriptive data are expressed
as the mean ± standard deviation. Fisher’s test and
independent sample T test are used for comparison
between groups. P<0.05 was taken as the statisti-
cally significant level.
 RESULTS 
We studied 109 biopsies in 86 cadaver renal trans-
plant patients (61 M, 25 F), with an average age of
47.4±12.9 years old at the time of study (Table I).
Overall 16 biopsies (14.7%; n=16/109) presented with
diffuse positive C4dPTCD. The incidence of +C4dPTCD
(Table I) was 13.5% (n=8/59) in the group within the
first six months of transplantation and 16% (n= 8
/50) after six months (p>0.05). 
The histological diagnoses are presented in Table
II. Half of the +C4d biopsies within the first six
months had a histological diagnosis of acute
humoral rejection (n= 4/8). Three out of four patients
with PTC C4d deposits had a final diagnosis of acute
humoral rejection (AHR) confirmed by histology,
C4dPTCD and circulating DSA. They were treated
with plasmapheresis, intravenous polyspecific im-
munoglobulin and anti-CD20. One patient lost his
graft; two currently maintain renal function with a
serum creatinine <2 mg/dl. 
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Table I
Patient characteristics and PTC C4d status
n=109 Total C4d+ C4d- p value
Total 109 16 93
Gender 81 M/28 F 15 M /1 F 66 M /27 F 0.065
Age (years) 47.4± 12.9 45.9±11.5 47.7±13.1 0.6095
Race 93 C/16 A 10 C/6 A 83 C/10 A 0.0130
Duration of dialysis pre-transplantation (months) 59.0±50.0 77.3±53.0 55.8±49.9 0.1142
Follow-up post-transplantation (months) 33.4±46.1 39.9±46.6 32.2±46.0 0.5379
HCV antibody positive 14/109 8 6 <0.0001
Previous transplantation 19/109 7 12 0.0070
Serum Creatinine (mg/dl) 3.5±1.8 3.5±1.7 3.4±2.2 0.7621
<6 m Follow up post-transplant 59/109 8 51
0.7896
≥6 m Follow up post-transplant 50/109 8 42
PRA<50% 98/109 11 87
0.0098
PRA≥50% 11/109 5 6
(M: male; F: female; C: Caucasian; A: African; PRA: panel reactivity antibodies; HCV: Hepatitis C virus)
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After six months, the majority of +C4d biopsies
(n=7/8) had evidence of interstitial fibrosis and tubu-
lar atrophy (IF/TA) and/or transplant glomerulopathy
(TG). In this last group of eight biopsies in six
patients, two patients subsequently died and four
lost their graft. 
During the three years of the study we found eight
biopsies with a histological diagnosis of transplant
glomerulopathy and 25% had deposits of C4d in PTC
(n=2/8). Within the TG group we detected one sam-
ple (16.6%) positive for circulating alloantibodies (1/ 6
patients screened).
Biopsies with C4d deposits (Table I) were obtained
on average 39.9±46.6 months after transplantation,
and presented a median serum creatinine of 3.5±1.7
mg/dl. There was no significant difference in creati-
nine levels between C4d PTC positive and negative
groups. The presence of C4dPTCD was more frequent
in biopsies from HCV antibody positive patients
(n=8/14; Fisher's test p<0.0001), with a previous renal
transplant (n=7/19; p=0.007) and with a PRA level
above 50% (n=5/11; p=0.0098). The HCV antibody
positive patients (Table III) have longer time on dial-
ysis (p=0.0019) and higher PRA (p=0.005) than the
HCV negative group. The small size of the popula-
tion precludes a multivariate analysis.
Circulating anti-HLA I/II alloantibodies (Table IV)
were studied in serum samples obtained from 46
biopsied patients (n=20 <6 month; n=26 ≥6 month).
Anti-HLA alloantibody were detected in 10.9% of
serum samples (n=5; >5% of reactivity), collected six
months after transplantation. There were no circu-
lating anti-HLA alloantibodies in 92.25% of the C4d
negative (n=37/40). 
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Table II
Histological diagnosis of PTC C4d positive group
<6 Months Acute humoral rejection 4/8
of transplantation Acute tubular necrosis 1/8
(4 patients/8 biopsies) Thrombotic microangiopathy 1/8
Calcineurin inhibitor toxicity 1/8
Normal kidney 1/8
≥6 Months Interstitial fibrosis/Tubular atrophy 7/8
of transplantation and/or transplant glomerulopathy
(6 patients/8 biopsies) Acute cellular rejection 1/8
Table III
Patient characteristics and HCV status
n =109
HCV positive HCV negative
P value
n = 14 n = 95
Creatinine ( mg/dl) 3.6±2.1 3.5±1.7 0.75
Duration of dialysis pre- 97.1±66.8 53.4±44.8 0.0019
transplant (month)


















Patient characteristics and anti-HLA class I/II alloantibodies 
n=46 Total Alloantibody positive Alloantibody negative P value
Total 46 5 41
Gender 31 M/15 F 2 M/ 3 F 29 M/12 F 0.311
Age (years) 45.5±14.1 36.6±14.3 46.6±13.8 0.1383
Race 41 C/5 A 5 C / 0 A 36 C/ 5 A 1.000
Duration of dialysis pre-transplantation (months) 57.5±49.3 20.2±15.4 62.1±50.1 0.0722
Follow-up post- transplantation (month) 41.7±47.7 71.4±15.2 38.1±49.2 0.1432
HCV antibody + 5/46 0/5 5/41 1.0000
Previous transplantation 8/46 5/5 3/41 0.0034
Serum Creatinine  (mg/dl) 3.3±1.6 2.7±1.7 3.4±1.6 0.3998
<6 month follow- up post-transplantation 20 0 20
0.0592
≥6 month follow up post transplantation 26 5 21
Positive PTC C4d 6 2 4
0.1199
Negative PTC C4d 40 3 37
PRA<50% 43 4 39
0.2978
PRA≥50% 3 1 2
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 DISCUSSION
 C4dPTCD and acute humoral rejection diagnosis
Since 2001, according to the 6th Banff Conference7,
being positive for C4dPTC is one of the three cardi-
nal features for AHR. 
Our study confirmed that C4d staining is more spe-
cific than the morphologic alterations usually pres-
ent in AHR. Staining for C4d is essential and must
be routinely made to allow early diagnosis and time-
ly treatment of AHR. The indirect two-step IF method
with the Quidel® monoclonal antibody used in our
study is the method recommended by the Banff cri-
teria and in the literature2. 
 C4d/alloantibodies and transplant 
glomerulopathy (TG)
In our study, the majority of biopsies from patients
with more than six months of transplantation and
positive C4dPTCD (n=7/8) had evidence of intersti-
tial fibrosis/tubular atrophy and/or TG. This group has
a worse outcome (two patients subsequently died
and four lost their graft).
We found an association of 25% between TG and
+ C4dPTCD (2/8 biopsies), the same as previously
described in the literature8,9. 
Originally classified as a variant of chronic allograft
nephropathy of unknown aetiology, TG is now recog-
nised with increased frequency in patients with a pri-
or history of humoral rejection, and is associated with
deposit of C4dPTC and circulating alloantibody, 
suggesting that TG may be one form of antibody-
-mediated injury8. In addition, capillary C4d deposi-
tion preceded the development of chronic TG in most
patients in whom serial biopsies were available,
emphasising the role of local complement activation
in the development of chronic TG in allograft10. 
The association of TG with severe peritubular cap-
illary basement membrane multilayering (PTCBMML)
had also been reported11. At present, the emerging pic-
ture is of an association between the presence of alloan-
tibody, capillary C4d deposition, TG and PTCBMML. This
combination of alloantibody (A), basement membrane
multilamination (B), C4d (C) and duplication of the
glomerular basal membrane (D) has been termed the
“ABCD tetrad” by Halloran and colleagues9. 
It is known that TG is associated with poor kid-
ney allograft survival and prior humoral rejection. The
risk of TG was demonstrated to be associated with
younger recipients, re-transplants, high panel reac-
tive antibodies pre-transplant, hepatitis C and acute
rejection, especially humoral rejection12. 
This issue could be of particular importance, as
at the present time there is no established treatment
for TG, and the presence of C4d deposits or anti-
HLA alloantibodies may indicate a need for alternati-
ve treatment strategies using intravenous Ig or anti-CD
20 (as shown by several recent running trials – indi-
cated at www.clinicaltrials.gov). 
 Circulating anti-HLA class I/II alloantibodies 
Development of new anti-HLA antibodies after kid-
ney transplantation is associated with higher rejec-
tion rates, severity of rejection and graft loss, mainly
when these antibodies are donor specific13. 
We found that in patients with renal dysfunction
a negative alloantibody screening is associated with
a reduced risk of C4dPTC deposits (<10%). We concur
with other authors14 that testing for post-transplant
HLA antibodies is a critical diagnostic tool for graft
dysfunction. It seems that antibody mediated re-
jection is very unlikely when the test is negative,
allowing other diagnostic possibilities to be pursued
early on, and mainly avoiding the need for invasive
tests such as allograft biopsies. Even so, these
results need to be established in a larger popula-
tion of patients.
 HCV and antibody mediated rejection
We found an association between C4dPTCD and
HCV antibody. This link has been previously described
but is not totally explained. Cosio et al.15 in 1996
found “acute vascular rejection” in 60% of HCV pos-
itive recipients compared with 28% in those with-
out HCV who underwent renal allograft biopsy. They
confirmed the previously reported association of HCV
and acute transplant glomerulopathy, but they do not
investigate the presence of deposition of C4d in PTC
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and so it is possible that they were in reality describ-
ing antibody-mediated rejection.
Our study shows that HCV patients have longer
time on dialysis and higher PRA, both risk factors
for presensitisation and antibody-mediated rejection. 
Similar results was been previously published by
Forman et al.16. They found like us that patients with
positive hepatitis C serology had higher rates of acute
humoral rejection (AHR), an association which lost
statistical significance after adjustment for higher PRA,
a known risk factor for AHR. 
A connection between the use of interferon-alpha
(IFN) in hepatitis C with acute rejection and graft loss
was been reported by Baid et al.17.  Their study may
explain the high rate of graft loss reported previously
in renal recipients receiving IFN, but cannot explain our
results as none of our patients were treated with IFN. 
 CONCLUSIONS
Our data suggest an association between +C4d PTC
deposits, 2nd transplant recipients, and the presence
of anti-HCV antibodies. The presence of antibody to
HCV does not seem to be a risk factor per se for the
appearance of C4d deposits, but reflects longer time
on dialysis and presensitisation with higher PRA. 
In patients with renal dysfunction, a negative allo-
antibody screening is associated with a reduced risk
of C4dPTC deposits (<10%). These data suggest that
monitoring anti-HLA antibodies may be a useful tool
for following-up antibody-mediated responses after
kidney transplantation.
It is still not known if a positive alloantibody screen
test without allograft dysfunction indicates an
increased risk of antibody-mediated pathology and
if graft biopsy is required. We believe that prospec-
tive monitoring of anti-HLA alloantibody will permit
diagnosis of subclinical acute humoral rejection and
a better knowledge of the importance of humoral
components in chronic allograft pathology.
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